Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

Scholar Rock Holding Corp (NASDAQ: SRRK) presented its Q1 2025 Business Update on May 14, highlighting significant progress toward the potential launch of its lead candidate apitegromab for Spinal ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Introduction & Market Context. Scholar Rock Holding Corp (NASDAQ: SRRK) presented its Q1 2025 Business Update on May 14, highlighting significant progress toward the potential launch of its lead ...

David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

Scholar Rock, a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein ...

Scholar Rock Holding (NASDAQ:SRRK) Corporation (NASDAQ:SRRK) is a clinical-stage biopharmaceutical company at the forefront of developing innovative medicines for serious diseases, with a particular ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and ...

Scholar Rock CHRO sells shares worth over $13k ...